Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

被引：0
|
作者：
Shuang Liu
Shoujing Zhao
Yang Dong
Tingting Wang
Xiaojia Niu
Lijing Zhao
Guan Wang
机构：
[1] Jilin University,Key Laboratory for Molecular Enzymology and Engineering, National Engineering Laboratory for AIDS Vaccine, The Ministry of Education, School of Life Sciences
[2] Jilin University,Department of Rehabilitation, School of Nursing
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
CUDC-907; Antitumor activity; Combination treatment; VS-5584; Pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：415 / 423
页数：8
相关论文
共 50 条
  • [21] Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Sakuta, Juri
    Ohyashiki, Kazuma
    BLOOD, 2015, 126 (23)
  • [22] Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
    Bao, Rudi
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Xu, Guang-Xin
    DellaRocca, Steven
    Borek, Mylissa
    Atoyan, Ruzanna
    Forrester, Jeffrey
    Samson, Maria
    Wang, Jing
    Zhai, Hai-Xaio
    Chan, Mendy
    Lai, Cheng-Jung
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2011, 71
  • [23] Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
    Liying Ma
    Xing Bian
    Wenchu Lin
    Journal of Experimental & Clinical Cancer Research, 40
  • [24] Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma
    Berdeja, Jesus G.
    Oki, Yasuhiro
    Patel, Manish R.
    Copeland, Amanda
    Flinn, Ian
    Neelapu, Sattva Swarup
    Viner, Jaye
    Wang, Jing
    Gerecitano, John F.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A PHASE 1 TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL INHIBITOR OF HDAC AND PI3K, IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA AND MULTIPLE MYELOMA
    Oki, Y.
    Berdeja, J.
    Patel, M.
    Flinn, I.
    Gerecitano, J.
    Neelapu, S.
    Copeland, A.
    Akins, A.
    Clancy, M.
    Viner, J.
    Wang, J.
    Ma, A.
    Younes, A.
    HAEMATOLOGICA, 2015, 100 : 109 - 110
  • [26] DUAL HDAC AND PI3K INHIBITOR CUDC-907 INHIBITS TUMOR GROWTH AND STEM-LIKE PROPERTIES VIA SUPPRESSING PTX3/CD44 IN NEUROBLASTOMA
    Sun, Feifei
    Hu, Yang
    Li, Meng
    Que, Yi
    Wang, Juan
    Hong, Ye
    Zhang, Li
    Zhen, Zijun
    Lu, Suying
    Huang, Junting
    Zhu, Jia
    Zhang, Yizhuo
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [27] The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer (vol 39, 219, 2020)
    Ma, Liying
    Bian, Xing
    Lin, Wenchu
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [28] Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer
    Ji, Meiying
    Li, Zhenling
    Lin, Zhenhua
    Chen, Liyan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (12): : 2402 - 2418
  • [29] CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
    Tu, Tian
    Huang, Jia
    Lin, Miaomiao
    Gao, Zhen
    Wu, Xiaoli
    Zhang, Wenjie
    Zhou, Guangdong
    Wang, Wenbo
    Liu, Wei
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 44 (05) : 1789 - 1800
  • [30] Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907
    Landsburg, Daniel J.
    Ramchandren, Rod
    Oki, Yasuhiro
    Pagel, John M.
    Lugtenburg, P. J.
    Gharavi, Robert
    Ma, Anna
    Hafeez, Amir
    Barta, Stefan Klaus
    BLOOD, 2017, 130
12345